News
Eli Lilly's growth is fueled by GLP-1 blockbusters and a solid pipeline, yet high valuations and reliance on key drugs ...
Eli Lilly is set to report Q2 2025 earnings on August 7, with consensus expecting $14.4 billion in revenue and $5.56 EPS, up 30-42% YoY. Learn more on LLY stock here.
Pharmaceutical Technology on MSN19h
Eli Lilly’s Mounjaro shows cardiovascular gains, but analysts underwhelmedA trial investigating the ability of Eli Lilly’s Mounjaro (tirzepatide) to reduce the risk of cardiovascular issues has met ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback